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1. SUMMARY 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in 
Western world, affecting 20-30% of the general population. NAFLD comprises a broad 
range of clinical disorders from pure steatosis and non-alcoholic steatohepatitis (NASH) to 
cirrhosis and liver cancer. However, the molecular mechanisms underlying NAFLD 
progression are not completely understood and the tools for its early diagnosis are limited. 
Notably, mitochondrial alterations have been described in a variety of chronic liver 
diseases, including NAFLD. Recently, MCJ, an inner mitochondrial membrane protein, has 
emerged as the first endogenous inhibitor of the electron transport chain complex I. In this 
project, we studied the role of MCJ in the pathogenesis of NAFLD and investigated the 
effect that the absence of MCJ exerts in the progression of the disease. Interestingly, we 
found that MCJ expression is increased during NAFLD. Moreover, MCJ silencing protected 
against hepatic lipid accumulation, liver injury and inflammation in the methionine-choline 
deficient mouse model of NASH. Apparently, loss of MCJ led to increased fatty acid β-
oxidation, Krebs cycle function, and glycolysis rate, which maintained mitochondrial 
respiration and ATP production through oxidative phosphorylation. In other words, these 
metabolic adaptations were able to counteract the cytotoxic effects of fat accumulation on 
mitochondria and ultimately on hepatocytes. Altogether, MCJ arises as a key regulator of 
NAFLD paving the way for new promising therapeutic approaches. 
2. INTRODUCTION 
2.1. LIVER PATHOPHYSIOLOGY 
The liver plays a central processing and distributing role in metabolism not only of 
carbohydrates, proteins and lipids, but also of hormones and drugs. Bile synthesis and 
immunity are other essential functions carried out by this organ.  
Liver disease is an important cause of morbidity and mortality worldwide. In 2013, more 
than 30 million Americans had liver disease (American Liver Foundation, 2016) and 29 
million people in the European Union (EU) suffered from a chronic liver condition 
(HEPAMAP EASL, 2016). Liver disease can be acute with fulminant liver failure or 
chronic and evolve over time to cirrhosis and liver cancer. Although liver disease is 
stereotypically linked to alcohol abuse or viral infections, bad dietary habits or excessive 
drug consumption have become new emerging risk factors. 
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2.2. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in 
Western world, affecting 20-30% of the general population (Sattar et al., 2014) and it is 
projected to be the leading indication for liver transplantation within a decade (Wong et al., 
2015). NAFLD is closely associated with obesity and features of the metabolic syndrome 
(hypertension, hyperlipidaemia, type 2 diabetes, and increased waist circumference), 
disorders with increasing prevalence worldwide (Brunt et al., 2015). 
NAFLD is a generic term that comprises a spectrum of clinical and histopathological 
disorders ranging from simple hepatic steatosis to a more complex pattern with 
inflammation (known as non-alcoholic steatohepatitis or NASH), fibrosis, cirrhosis and 
ultimately hepatocellular carcinoma (HCC), in the absence of alcohol intake. Although 
steatosis can be reversible, up to 44% of steatosis may progress to NASH (McPherson et 
al., 2015), which is a significant risk factor for hepatic cirrhosis and HCC. According to the 
World Health Organization (WHO), in 2013, liver cirrhosis accounted for around 170,000 
deaths in Europe and liver cancer accounted for around 47,000 deaths in the EU.  
The “two-hit” model proposed by Day and James (1998) is currently the most accepted 
theory for NAFLD pathogenesis. According to this hypothesis, simple steatosis, as a result 
of insulin resistance and excessive fatty acid influx, constitutes the first hit. The first hit 
sensitises the liver to a second hit, which likely involves oxidative and endoplasmic 
reticulum (ER) stress, lipid peroxidation, and mitochondrial dysfunction. Thus, the second 
hit triggers hepatocyte damage and death, inflammation and fibrosis, and promotes disease 
progression from steatosis to NASH. 
Hepatic steatosis or fat accumulation mainly in the form of triglycerides (TGs) in the 
cytoplasm of hepatocytes is the hallmark for NAFLD diagnosis. Dietary fats, circulating 
free fatty acids (FFAs) from lipolysis of adipose tissue, and de novo lipogenesis (DNL) are 
the main lipid sources of hepatocytes. Steatosis reflects a disordered homeostasis of lipid 
metabolism when lipid inputs exceed lipids utilized.  
At the early stages of NAFLD, β-oxidation and very-low-density lipoprotein (VLDL) 
secretion are enhanced, possibly as a compensative mechanism in response to the overload 
of hepatic FFAs. β-oxidation in mitochondria provides energy (ATP) for the liver through 
the electron transport chain (ETC) and oxidative phosphorylation (OXPHOS). Due to 
electron leak in complexes I and III of the ETC, mitochondria become the major source of 
reactive oxygen species (ROS) production in cells. Thus, oxidative stress is produced in 
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hepatocytes as a result of an increased fatty acid oxidation (FAO). When β-oxidation and 
VLDL export are unable to utilize the overloaded FFAs, excessive FFAs will be esterified 
into TGs and stored in lipid droplets, resulting in hepatic steatosis.  
Overproduction of ROS can lead to mitochondrial dysfunction. Impaired ATP homeostasis 
(Cortez-Pinto et al., 1999) and defective ETC (Perez-Carreras et al., 2003) are common 
indications of mitochondrial dysfunction and have been well documented in NAFLD. 
Prolonged oxidative stress can activate the JNK pathway, which may trigger hepatocyte 
apoptosis. Moreover, high ROS levels can directly induce the transcription of 
proinflammatory cytokines (TNF-α, IL-6) through NFκB and activate the resident 
macrophages in the liver or Kupffer cells, which play a pivotal role in the inflammation 
during NASH by recruiting inflammatory cells (Baffy, 2009). Kupffer cells also help 
perpetuating liver injury by activating hepatic stellate cells (HSCs) through actions of 
several fibrogenic cytokines, especially TGF-β. HSCs are the key cells involved in fibrosis, 
which is a wound healing response characterized by an excessive deposition of collagen and 
other extracellular matrix (ECM) molecules resulting in formation of scar tissue and poor 
liver function. 
Lifestyle modification focused on healthy eating, weight loss (when needed) and regular 
exercise or even bariatric surgery has been shown to revert hepatic steatosis. However, 
there is clearly a need for pharmacological therapy to treat the acute stages of NAFLD 
(Musso et al., 2016). 
2.3. METHYLATION-CONTROLLED J (MCJ) PROTEIN  
MCJ, also known as DnaJC15, is a small protein (147 amino acids) member of the DnaJC 
subfamily of cochaperones. Unlike other DnaJ proteins, MCJ is not soluble since it contains 
a transmembrane domain. MCJ was first reported in human ovarian cancer cell lines, where 
mcj gene expression was found to be negatively regulated by methylation and correlated 
with increased chemoresistance (Shridhar et al., 2001). 
Hatle et al. (2013) identified the mouse ortholog of MCJ and showed that MCJ resides in 
the inner mitochondrial membrane of highly metabolic tissues (heart, liver and kidney) and 
immune cells. Within mitochondria, MCJ associates with and negatively regulates complex 
I of the ETC, becoming the first endogenous inhibitor. Importantly, Hatle et al. (2013) 
proved that MCJ deficiency leads to increased complex I activity, hyperpolarization of 
mitochondria, and increased generation of ATP, without affecting mitochondrial mass. 
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Normally, increased mitochondrial membrane potential (MMP) is associated with increased 
ROS due to the escape of electrons from transport chain. In contrast, the absence of MCJ 
enhanced complex I activity and accumulation of H+ in the intermembrane space, but it did 
not increase ROS. In mammalian cells, especially hepatocytes and cardiomyocites, 
supercomplexes containing complexes I, III and IV have been characterized and defined as 
“respirasomes” (Acin-Perez et al., 2008). The functions of the supercomplexes are likely to 
facilitate the transfer of electrons between complexes and to minimize the risk of releasing 
electrons that lead to ROS formation. It is therefore possible that the lack of MCJ facilitates 
the formation of supercomplexes, leading to overall increased complex I activity and MMP 
but no increase in ROS. 
While under normal physiological conditions MCJ is dispensable, enhanced mitochondrial 
respiration in the absence of MCJ prevents the pathological accumulation of lipids in the 
liver under altered metabolic conditions, such as fasting and a high-cholesterol diet (Hatle et 
al., 2013). 
3. OBJECTIVES 
Restoring the mitochondrial ETC activity in NAFLD could mitigate oxidative stress, which 
plays an important role in cell death, inflammation and fibrosis. Interestingly, MCJ has 
recently emerged as a novel endogenous inhibitor of ETC complex I. Taken together, the 
aim of this project is to study the role of the mitochondrial protein MCJ in the development 
of NAFLD and investigate the effect that the absence of MCJ exerts in the progression of 
the disease. 
4. MATERIALS AND METHODS 
Experimental procedures in animals were approved by the CIC bioGUNE Animal Care and 
Use Committee according to the criteria outlined in the “Guide for the Care and Use of 
Laboratory Animals” prepared by the National Academy of Sciences.  
4.1. MCJ IN VIVO SILENCING OF MICE 
Three-months-old male WT C57BL/6J mice (Jackson Laboratories) were fed a methionine 
(0.1%) and choline (0%) deficient diet (MCDD), an established model of NASH (Rinella et 
al., 2008). One week later, they were separated into two groups, each of which received 
twice (once a week) either 200 µl of a 0.75-µg/µl solution of MCJ-specific siRNA or 
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control siRNA using Invivofectamine® 3.0 Reagent (Thermo Fisher Scientific), through tail 
vein injection. Animals were sacrificed 4 weeks after the beginning of the diet. 
4.2. HISTOLOGY 
Paraffin-embedded sections of formalin-fixed liver samples were deparaffinised and 
rehydrated. Tissue sections were stained with haematoxylin and eosin (H&E), Sudan III, 
Sirius red, F4/80 antibody and periodic acid–Schiff (PAS) according to the CIC bioGUNE 
Histology Service routine procedures. Images were taken with a 20x objective from an Axio 
Imager A1 upright light microscope (Zeiss). 
4.3. MITOCHONDRIA ISOLATION 
Mitochondrial extracts from hepatic tissue were obtained using the Mitochondrial 
Fractionation Kit (ActiveMotif). Basically, lysis was performed in a pestle homogenizer 
using the gentle cytosolic buffer. The cellular lysate was subjected to several 
centrifugations to obtain crude mitochondria pellets.  
4.4. PROTEIN ISOLATION AND WESTERN BLOTTING 
After hepatic tissue homogenization (Precellys24, Bertin Instruments), addition of RIPA 
lysis buffer (protease inhibitor, sodium deoxycholate, 1 M NaF, 0.1 M ortovanadate) 
enabled total or mitochondrial fraction protein extraction. Protein was quantified by the 
BCA assay (Thermo Scientific) with a BSA standard curve. The extracted protein was 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to nitrocellulose membranes or polyvinylidene difluoride (PVDF) membranes in 
the case of MCJ. The anti-mouse MCJ rabbit polyclonal antibody was generated as 
previously described by Hatle et al. (2013). JNK antibody is from Cell Signalling and 
JNK1/2 pT183/Y185 from Invitrogen. Apolipoprotein B antibody is from Chemicon 
International. As controls, GAPDH antibody (Abcam) or COXIV (Cell Signalling) were 
used. As secondary antibodies, anti-rabbit-IgG-HRP-linked (Cell Signalling), anti-mouse-
IgG-HRP-linked (Santa Cruz Biotechnology) and anti-goat-IgG-HRP-linked (Santa Cruz 
Biotechnology) were used. Immunoreactive proteins were detected by Clarity ECL 
Substrate (BioRad), and exposed to X-ray films (Amersham) in a Curix 60 Developer 
(AGFA).  
4.5. RNA ISOLATION AND QUANTITATIVE REVERSE TRANSCRIPTION 
POLYMERASE CHAIN REACTION (RT-qPCR) 
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Total RNA was extracted from frozen liver with TRIzol reagent (Invitrogen). RNA 
concentration and purity was determined using NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific). 1-2 µg of total RNA was treated with DNAse (Invitrogen) and reverse 
transcribed into cDNA using M-MLV Reverse Transcriptase (Invitrogen) and random 
primers. Quantitative PCR was performed using SYBR® Select Master Mix (Applied 
Biosystems) and the ViiA7 Real-Time PCR System (Applied Biosystems). Primers were 
designed using the NCBI tool Primer-BLAST and provided by Sigma-Aldrich 
(Supplementary Table 1). The Ct values were extrapolated to a standard curve, and data 
was then normalized with the housekeeping expression (GAPDH).  
4.6. MALATE DEHYDROGENASE 2 (MDH2) ACTIVITY ASSAY 
Mitochondrial malate dehydrogenase (MDH2) activity was measured in mouse liver 
extracts using the Abcam Kit. The enzyme was inmunocaptured within the wells of the 
microplate and activity was determined by following the production of NADH. The 
generation of NADH is coupled to the 1:1 reduction of a reporter dye to yield a coloured 
reaction product whose concentration can be monitored by measuring the increase in 
absorbance at 450 nm.  
4.7. RESPIRATION STUDIES IN ISOLATED LIVER MITOCHONDRIA 
Liver mitochondrial respiration was measured at 37 °C by high-resolution respirometry 
using the Seahorse XF24-3 Extracellular Flux Analyzer (Agilent Technologies). For the 
measurement of the oxygen consumption rate (OCR), fresh liver mitochondria were isolated 
and plated in a XF24 cell culture microplate (Agilent Technologies), 5 µg per well. 
Mitochondria were incubated in a media containing substrates for both complexes I and II: 
glutamate (10 mM), malate (2 mM) and succinate (10 mM), in order to measure basal 
respiration. The instrument performed sequential compound addition and mixing while real 
time calculation of OCR. Firstly, ADP (4 mM) was added to asses “state 3” respiration, 
which is the actively respiring state. Then, the addition of ATP synthase inhibitor 
oligomycin (3 µM), allowed measurement of ATP-coupled oxygen consumption through 
OXPHOS. Carbonyl cyanide 4-trifluoromethoxy-phenylhydrazone (FCCP) (4 µM) is an 
uncoupling agent that allows maximum electron transport, and therefore measurement of 
proton leak. Finally, antimycin A (4 µM) and rotenone (2 µM), mitochondrial complex III 
and I inhibitors respectively, were performed to determine non-mitochondrial respiration. 
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The OCR values, expressed as pmol of O2 per minute, were normalized with the total 
amount of protein quantified through the BCA method. 
4.8. ATP LEVELS DETERMINATION 
Intracellular ATP levels were determined in vivo and in vitro using the ATPlite 
luminescence assay system (PerkinElmer). 
4.9. MCJ IN VITRO SILENCING OF PRIMARY MOUSE HEPATOCYTES  
Hepatocytes were isolated from male C57BL/6J WT mice via collagenase perfusion. They 
were seeded at a density of 500,000 cells per collagen-coated culture well in fresh 10%-
fetal bovine serum (FBS) minimum essential medium (MEM) (Gibco) supplemented with 
1% penicillin, streptomycin and glutamine PSG (Invitrogen). In order to mimic NAFLD in 
vitro, primary hepatocytes were incubated overnight with 0% FBS MEM 1% PSG medium 
containing 400 µM oleic acid, and 1 µM rotenone (Sigma-Aldrich) was added 6 hours 
before cell harvesting. WT primary hepatocytes were transfected with 100 nM MCJ siRNA 
using Jetprime reagent (Polyplus). Controls were transfected with an unrelated siRNA 
(Qiagen).  
4.10. BODIPY STAINING 
Hepatocytes seeded in collagen-coated coverslips were incubated with BODIPY 493/503 
(Molecular Probes) at a concentration of 10 µg/ml during 30 min. prior to fixation with 4% 
paraformaldehyde. DAPI (1 µg/ml) was added to the mounting medium. Images were taken 
with a 40x objective from an Axio Imager D1 fluorescence microscope (Zeiss). 
Quantification of lipid bodies was performed using Frida Software. 
4.11. STATISTICAL ANALYSIS  
Statistical significance was determined by two-way analysis of variance followed by a 
Student’s t test using GraphPad Prism software. 
5. RESULTS  
5.1. MCJ EXPRESSION IS INCREASED IN NAFLD 
Three-months-old WT C57BL/6 mice were fed for 4 weeks a MCDD, a well-established 
animal model of acute NAFLD. As in human disease (data not shown), MCDD-induced 
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NAFLD resulted in MCJ protein overexpression in mice (Figure 1). These data suggest a 
role for elevated levels of MCJ in the pathogenesis of NAFLD. We therefore wondered if 
MCJ silencing could benefit the understanding of the disease and the development of new 
drugs for its treatment.  	
 
 
 
 
 
 
Figure 1. MCJ expression is regulated in NAFLD. Western blot analysis of MCJ expression in liver mitochondria of 
control and MCDD fed WT mice. MCJ protein was separated in a 15% (w/v) polyacrylamide gel. Complex IV 
(COXIV), a mitochondrial housekeeping, was resolved in a 11% (w/v) polyacrylamide gel. 
 
 
5.2. MCJ SUPRESSION ATTENUATES MCDD-INDUCED LIVER INJURY 
MCJ silencing was confirmed by Western blotting (Figure 2A). Western blot analysis 
showed that MCJ silencing was associated with insignificant JNK phosphorylation and 
therefore negligible triggering of apoptosis, compared to WT MCDD fed mice (Figure 2B). 
Importantly, mouse liver specimens provided by the CIC bioGUNE Histology Service 
revealed significantly reduced lipid content, fibrosis and inflammation in MCJ deficient 
animals (Figure 2C). 
 
Figure 2. MCJ suppression attenuates MCDD-induced liver injury. (A) MCJ in vivo silencing confirmation by 
Western blotting in MCDD fed mice. MCJ protein and GAPDH, a cytosolic housekeeping, were resolved in a 15% 
(w/v) polyacrylamide gel. (B) Western blot analysis of total JNK and pJNK expression measured in liver of WT 
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and siMCJ MCDD fed mice. Proteins were resolved in a 11% (w/v) polyacrylamide gel. (C) Liver injury analysis 
based on histological samples of WT and siMCJ MCDD fed mice. Haematoxylin and eosin (H&E) stain is used 
for demonstration of cytoplasmic inclusions in pathological specimens. Sudan III enables detection of lipid 
accumulation within hepatocytes. Sirius red colours collagen fibres I and III and it is used to evaluate fibrosis levels. 
Anti-F4/80 antibody recognises a glycoprotein expressed by murine macrophages and it is used for inflammation 
assessment. 
 
5.3. MCJ DEFICIENCY RESTORES FATTY ACID CATABOLISM IN THE 
LIVER 
In NAFLD, hepatic fat accumulation could be mainly explained by: 1) enhanced fatty acid 
synthesis by DNL, 2) decreased VLDL export or 3) reduced capacity of β-oxidation. In 
order to determine the mechanism by which MCJ regulates hepatic lipid accumulation 
during NAFLD, we carried out the following assays. 
Patricia Aspichueta´s group at the University of the Basque Country evaluated DNL by 
measuring the incorporation of [3H]-acetate and reported no variations between siMCJ and 
control mouse livers (Supplementary Figure 1). Moreover, since VLDL secretion, 
measured as ApoB100 expression in serum, remained unaltered in both animal groups 
(Figure 3A), a regulation at the FAO level became our strong candidate.  
Interestingly, PCR analysis revealed an overall increased gene expression in siMCJ MCDD 
fed mice of several proteins directly (CPT1, ACADM, ACADL, FATP2, ABCD1) and 
indirectly (PGC1α, NRF2) involved in FAO (Figure 3B). In other words, a reduced hepatic 
β-oxidation function driven by MCJ is thought to be the underlying cause of lipid 
accumulation during NAFLD. 
Malate dehydrogenase enzymatic activity, which was used to evaluate the tricarboxylic acid 
(TCA) cycle activity, was significantly increased in siMCJ livers (Figure 3C). 
Consequently, the acetyl-CoA resulting from β-oxidation is meant to continue degradation 
into CO2 in the TCA cycle and further energy production through the ETC and OXPHOS. 
Liver mitochondrial respiration was evaluated by measurement of the OCR using Seahorse 
respirometry. siMCJ mouse livers showed significantly higher basal and “state 3” 
respiration than WT MCDD fed mice (Figure 3D). Moreover, ATP levels, which have been 
reported to be reduced during NAFLD, were significantly elevated in the absence of MCJ 
and comparable to control healthy animals (Figure 3E). These results are consistent with 
the previously described role of MCJ as a negative regulator of the ETC complex I under 
pathological conditions.  
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Figure 3. MCJ deficiency restores fatty acid catabolism in the liver. (A) Western blot analysis of ApoB100 
expression measured in serum of WT and siMCJ MCDD fed mice. The protein was resolved in a 7% (w/v) 
polyacrylamide gel. Ponceau staining of nitrocellulose membranes was used as a loading control. (B) mRNA 
expression analysis of FAO related genes measured in WT and siMCJ MCDD fed mice. The tested genes 
encode for carnitine palmitoyltransferase 1 (CPT1), medium-chain acyl-CoA dehydrogenase (ACADM), long-chain 
acyl-CoA dehydrogenase (ACADL), fatty acid transport protein 2 (FATP2), ATP binding cassette subfamily D 
member 1 (ABCD1), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1a) and nuclear 
factor erythroid 2-related factor 2 (NRF2). Data was normalized to GAPDH housekeeping expression. (C) Malate 
dehydrogenase 2 (MDH2) activity assay measured in liver extracts of WT and MCDD fed mice. Enzymatic 
activity was expressed as product concentration (measured as the increase in absorbance at 450 nm) and divided by 
time. (D) Seahorse analysis of ETC and OXPHOS activity measured in WT and siMCJ MCDD fed mice. Liver 
mitochondria had been previously incubated in a media containing substrates for both complexes I and II to establish 
the OCR baseline. Then, the OCR was calculated while sequential addition of pharmacologic compounds: ADP, 
oligomycin, FCCP, and rotenone + antimycin A. (E) Intracellular ATP production measured in liver of WT and 
siMCJ MCDD fed mice and compared with healthy control mice. (*p<0.05) 
 
 
5.4. MCJ SILENCING INCREASES HEPATIC GLYCOLYSIS AND 
GLYCOGENESIS 
Since the absence of MCJ leads to increased TCA cycle, mitochondrial ETC and ATP 
production through OXPHOS, we considered a regulation in the glycolytic pathway. PCR 
analysis proved that the genes involved in the first phase of the glycolysis (HK2, HK4, 
FBP1) and gluconeogenesis (PFKL), were overexpressed in siMCJ livers compared to 
controls (Figure 4A). Moreover, histological samples provided by the CIC bioGUNE 
Histology Service showed glycogen deposition in the liver of siMCJ MCDD fed mice 
(Figure 4B). These results suggest that the absence of MCJ also regulates carbohydrate 
metabolism to maintain mitochondrial function during NAFLD and to store excess energy. 
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Figure 4. MCJ silencing increases hepatic glycolysis and glycogenesis. (A) mRNA expression analysis of 
glycolysis and glyconeogenesis genes measured in livers from WT and siMCJ MCDD fed mice. The tested 
genes encode for hexokinase 2 (HK2), glucokinase (HK4), fructose-bisphosphatase 1 (FBP1) and liver type 
phosphofructokinase (PFKL). Data was normalized with GAPDH housekeeping expression. (*p<0.05) (B) Histology-
based demonstration of glycogen storage in the liver of siMCJ MCDD fed mice through PAS staining. 
 
 
5.5. MCJ-DEPENDENT FATTY ACID CATABOLISM IS REGULATED BY 
ELECTRON TRANSPORT CHAIN COMPLEX I ACTIVITY 
The above exposed results were verified in vitro by evaluating lipid bodies with BODIPY 
fluorescent staining (Figures 5A and 5B) and ATP production (Figure 5C) in isolated 
mouse primary hepatocytes. Accordingly, when treating hepatocytes with steatotic doses of 
oleic acid, MCJ silencing prevented cells from lipid accumulation and OXPHOS 
perturbation, in contrast with WT hepatocytes. However, the addition of rotenone, an 
exogenous ETC complex I inhibitor, reverted siMCJ hepatocytes to a pathological situation 
characterised by abundant lipid droplets and depletion of ATP intracellular levels. These 
results demonstrate that MCJ regulates β-oxidation and ATP production in the liver through 
complex I activity and could be useful for the treatment of NAFLD.  
HK
2
HK
4
FB
P1
PF
KL
0
2
4
6
8
10
12
nm
ol
/m
g 
pr
ot
ei
n
Control
siMCJ*
*
*
*
m
R
N
A
 e
xp
re
ss
io
n W
T 
PAS 
si
M
C
J 
A B 
100 µm	
	 12	
	
 
 
Figure 5. MCJ-dependent fatty acid catabolism is regulated by electron transport chain complex I activity. (A) 
BODIPY staining of lipid droplets in WT and siMCJ primary hepatocytes treated with steatotic doses of oleic 
acid (OA) in the absence and in presence of complex I inhibitor, rotenone. (B) Lipid body quantification 
using Frida Software. (C) Intracellular ATP levels determination. (*p<0.05, ** p<0.01, ***p<0.001) 
 
 
6. DISCUSSION  
Since mitochondrial protein MCJ is expressed during murine NASH but not in healthy 
animals (Figure 1), we considered silencing MCJ to further investigate the molecular 
mechanisms involved in the development of the disease. Thus, MCJ depletion revealed an 
increased activity of FA catabolism as mitochondrial β-oxidation (Figure 3B), TCA cycle 
(Figure 3C), ETC (Figure 3D) and OXPHOS (Figure 3E) were increased in MCDD fed 
mouse livers. Moreover, the glycolytic pathway was enhanced too (Figure 4A), possibly to 
feed the demands of an incredibly functional ETC. As a matter of fact, the accumulation of 
ATP and glycerol as a result of an increased lipid catabolism can be sensed by the liver as a 
signal to initiate gluconeogenesis to store the surplus energy in the form of glycogen 
(Figure 4B). We further verified in vitro that the enhancement of lipid oxidation was 
regulated by MCJ. Interestingly, addition of exogenous inhibitor of complex I rotenone to 
steatotic hepatocytes reverted the recovered situation driven by siMCJ back to pathological 
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(Figure 5). Surprisingly, despite an increased ETC activity, no ROS production was 
detected. Conversely, a reduction in apoptosis (Figure 2B), inflammation and fibrosis 
(Figure 2C) was observed, as Hatle et al. (2013) had also described before. Summing up, 
the liver specific deletion of the respiratory chain inhibitor MCJ attenuates the progression 
of NAFLD by enhancing β-oxidation. 
Altogether, our final hypothesis of NAFLD pathogenesis is as follows. We suggest that 
inner mitochondrial membrane protein MCJ is able to bind and inhibit ETC complex I and 
the subsequent association of complex III to form supercomplexes. On the one hand, 
complex I inhibition may lead to a decreased mitochondrial respiration activity and 
OXPHOS. Moreover, the feeder pathways for ETC may be slowed down too. β-oxidation is 
directly linked to ETC through the TCA cycle. Thus, mitochondrial dysfunction, which is 
implicated in the pathogenesis of most liver diseases, might impair the oxidation of FAs 
leading to lipid accumulation within the liver, also known as hepatic steatosis (Day and 
James´s first hit). On the other hand, hampered supercomplex formation could lead to an 
inefficient transfer of electrons between complexes favouring electron leakage and 
subsequent ROS formation. Prolonged oxidative stress would trigger apoptosis, 
inflammation and fibrosis, and therefore exacerbate NAFLD progression to a more acute 
state (Day and James´s second hit) that could finally end in cirrhosis or even HCC. 
7. CONCLUSION  
The unravelling of NAFLD pathogenesis has led us to introduce MCJ as a druggable target 
that could help revert hepatic steatosis as well as NASH. Importantly, MCJ is detectable in 
the sera of NAFLD patients (data not shown), suggesting its value as a biomarker for the 
disease that would probably overcome the inconvenience of liver biopsy. 
Additionally, parallel experiments conducted by Mª Luz Martinez-Chantar´s group have 
extended MCJ applications to drug induced liver injury (DILI) prevention and treatment, 
another major risk factor for acute liver failure nowadays. Several drugs, such as 
paracetamol, have been described to target mitochondrial dysfunction. It is possible that 
highly reactive paracetamol metabolites promote the interaction of MCJ with complex I, 
thereby interfering with formation of supercomplexes in the liver. Thus, the repression of 
MCJ expression seems to avoid hepatotoxicity by sustaining the formation of 
supercomplexes. 
Fortunately, results from a number of on-going clinical trials have revealed that siRNA 
treatment is an efficient therapeutic approach to target genes in the liver (Wittrup and 
	 14	
Lieberman, 2015). Likewise, siRNA-targeting MCJ may also show efficacy for the 
treatment of NAFLD, DILI and presumably other liver disorders associated with 
mitochondrial dysfunction. 
Finally, it is worth mentioning that MCJ suppression cannot always be considered as a 
beneficial approach. For example, low MCJ expression in breast cancer cells has proved to 
promote chemoresistance (Fernandez-Cabezudo et al., 2016). Apparently, loss of MCJ 
expression could provide the necessary energy for cancer growth and ABC drug efflux 
transporters, which are highly dependent on mitochondria-derived ATP. In contrast with 
NAFLD and DILI therapeutic strategies, MCJ agonists could be used in combination with 
standard chemotherapeutic drugs to overcome chemoresistance, not only in primary 
cancers, but also in metastatic cancers that are highly refractory to any conventional 
therapies. 
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SUPPLEMENTARY DATA 
Supplementary Table 1. Sequence of primers used for RT-qPCR. 
Gene name Symbol Sequence 
ATP Binding Cassette 
Subfamily D Member 1 ABCD1 
Forward 5’-GACTCCGGAACAAACGTGAGG-3' 
Reverse 5’-CTTCATCTTGCCCTCGTCCA-3' 
Acyl-CoA 
Dehydrogenase, Long 
Chain 
ACADL 
Forward 5’-GTCCGATTGCCAGCTAATGC-3' 
Reverse 5’-CACAGGCAGAAATCGCCAAC-3' 
Acyl-CoA 
Dehydrogenase, Medium 
Chain 
ACADM 
Forward 5’-TCAAGATCGCAATGGGTGCT-3' 
Reverse 5’-GCTCCACTAGCAGCTTTCCA-3' 
Carnitine 
Palmitoyltransferase 1 CPT1 
Forward 5’-GACTCCGCTCGCTCATTCC-3' 
Reverse 5’-GAGATCGATGCCATCAGGGG-3' 
Fatty Acid Transport 
Protein 2 FATP2 
Forward 5’-CCGCAGAAACCAAATGACCG-3' 
Reverse 5’-TGCCTTCAGTGGATGCGTAG-3' 
Fructose-Bisphosphatase 
1 FBP1 
Forward 5’-GTCTGTTTCGATCCCCTTGA-3' 
Reverse 5’-TCCAGCATGAAGCAGTTGAC-3' 
Glyceraldehyde-3- 
phosphate dehydrogenase  GAPDH 
Forward 5'-CGTCCCGTAGACAAAATGG-3'  
Reverse 5'-TTGATGGCAACAATCTCCAC-3'  
Hexokinase 2 HK2 
Forward 5’-GGGTAGCCACGGAGTACAAA-3' 
Reverse 5’-TGGATTGAAAGCCAACTTCC-3' 
Hexokinase 4 HK4 
Forward 5’-CTTTCCAGGCCACAAACATT-3' 
Reverse 5’-TGAGTGTTGAAGCTGCCA TC-3' 
Nuclear Factor Erythroid 
2-Related Factor 2 NRF2 
Forward 5’-TGTAGGGTGGGGGTACAAAG-3' 
Reverse 5’-GAATCGGCGCTAAGGAACCC-3' 
Phosphofructokinase, 
Liver Type PFKL 
Forward 5’-CATATATGTGGGGGCCAAAG-3' 
Reverse 5’-GACACACAGGTTGGTGATGC-3' 	 	
	 (ii)	
PPAR-gamma 
Coactivator 1 alpha PGC1a 
Forward 5’-AGACAGGTGCCTTCAGTTCAC-3’ 
Reverse 5’-ACCAGAGCAGCACACTCTATG-3’ 
 
 
	
Supplementary Figure 1. DNL of fatty acids (FA), diglycerides (DG), triglycerides (TG), plasma phospholipids 
(PL) and cholesterol esters (CE) in livers from WT and siMCJ mice after the MCDD by measuring the 
incorporation of  [3H]-acetate. Radioactivity was measured in a scintillation counter and expressed as 
disintegrations per minute (dpm). 
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